GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a ...

Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier ...

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to ...

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates ...

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly ...

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a potential treatment for chemotherapy-induced peripheral neuropathy. | Amid the rise of ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...

TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs. | TCR-T ...

The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to ...

GSK has linked its mRNA seasonal flu vaccine candidate to higher immune responses than conventional jabs in a phase 2 trial, ...

Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 ...